270 participants
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-07
- Start Date:
- 2026-05-21
- Completion:
- 2033-07-27
Conditions
- High Risk Smoldering Multiple Myeloma (HR-SMM)
Interventions
- DRUG
No Results Yet